| Mr Mark A Vaughan, MD | |
|
3256 Professional Dr, Auburn, CA 95602-2412 | |
| (530) 886-8630 | |
| (530) 886-8629 |
| Full Name | Mr Mark A Vaughan |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 28 Years |
| Location | 3256 Professional Dr, Auburn, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053303461 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | A67399 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Progressive Home Care - Auburn | Auburn, CA | Home health agency |
| Sutter Auburn Faith Vna & Hospice | Auburn, CA | Home health agency |
| Sutter Auburn Faith Vna & Hospice-hospice | Auburn, CA | Hospice |
| Vitas Healthcare Corporation Of California | Sacramento, CA | Hospice |
| Sutter Auburn Faith Hospital | Auburn, CA | Hospital |
| Sutter Medical Center, Sacramento | Sacramento, CA | Hospital |
| Sutter Roseville Medical Center | Roseville, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Auburn Medical Group, Inc | 6800890179 | 3 |
News Archive
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
Fundamental differences between how the brain forms during adolescence have been discovered in children with schizophrenia and their siblings, a new study shows. The study opens up new avenues for researchers to explore when developing treatment for the illness, which can be hugely debilitating for children.
Visiting Physicians Association, which is based in Farmington Hills, Mich., will pay the United States and the state of Michigan $9.5 million to settle allegations that the association violated the False Claims Act by submitting false claims to Medicare, TRICARE and the Michigan Medicaid program, the Justice Department announced today. Visiting Physicians Association is a Michigan professional corporation which has provided home health services at various times in Michigan, Ohio, Georgia and Wisconsin.
Diagnosing colorectal cancer is complex; it relies on significant invasive tests and subjective evaluations. This process may soon become much easier thanks to a medical breakthrough by scientists at the Research Institute of the McGill University Health Centre.
› Verified 4 days ago
| Entity Name | Auburn Medical Group, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720192560 PECOS PAC ID: 6800890179 Enrollment ID: O20060830000159 |
News Archive
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
Fundamental differences between how the brain forms during adolescence have been discovered in children with schizophrenia and their siblings, a new study shows. The study opens up new avenues for researchers to explore when developing treatment for the illness, which can be hugely debilitating for children.
Visiting Physicians Association, which is based in Farmington Hills, Mich., will pay the United States and the state of Michigan $9.5 million to settle allegations that the association violated the False Claims Act by submitting false claims to Medicare, TRICARE and the Michigan Medicaid program, the Justice Department announced today. Visiting Physicians Association is a Michigan professional corporation which has provided home health services at various times in Michigan, Ohio, Georgia and Wisconsin.
Diagnosing colorectal cancer is complex; it relies on significant invasive tests and subjective evaluations. This process may soon become much easier thanks to a medical breakthrough by scientists at the Research Institute of the McGill University Health Centre.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Mark A Vaughan, MD 3256 Professional Dr, Auburn, CA 95602-2412 Ph: (530) 886-8630 | Mr Mark A Vaughan, MD 3256 Professional Dr, Auburn, CA 95602-2412 Ph: (530) 886-8630 |
News Archive
Janssen-Cilag International NV announced today that the European Commission has approved the use of VELCADE (bortezomib) as induction therapy (a first therapeutic option) in combination with dexamethasone or thalidomide and dexamethasone. This licence extension will apply to adult patients with previously-untreated multiple myeloma who are eligible for high-dose chemotherapy with haematological stem cell transplantation.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
Fundamental differences between how the brain forms during adolescence have been discovered in children with schizophrenia and their siblings, a new study shows. The study opens up new avenues for researchers to explore when developing treatment for the illness, which can be hugely debilitating for children.
Visiting Physicians Association, which is based in Farmington Hills, Mich., will pay the United States and the state of Michigan $9.5 million to settle allegations that the association violated the False Claims Act by submitting false claims to Medicare, TRICARE and the Michigan Medicaid program, the Justice Department announced today. Visiting Physicians Association is a Michigan professional corporation which has provided home health services at various times in Michigan, Ohio, Georgia and Wisconsin.
Diagnosing colorectal cancer is complex; it relies on significant invasive tests and subjective evaluations. This process may soon become much easier thanks to a medical breakthrough by scientists at the Research Institute of the McGill University Health Centre.
› Verified 4 days ago
Dr. Chun Yih Yang, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 11670 Atwood Rd, Auburn, CA 95603 Phone: 530-887-2800 | |
Zaman Javaheri, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 14561 Curry Ct, Auburn, CA 95602 Phone: 949-290-8546 |